Option chain shows key data for Karyopharm Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Karyopharm Therapeutics.

Karyopharm Therapeutics (NASDAQ:KPTI) Stock, Option Chain

Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AKTS

ATCH

BTCT

EWTX

FUFU

IPHA

KPTI

KTOS

LAES

PRTC

RDZN

SGMT

SIDU

SMCI

STEC

TNXP

UBXG

XXII

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

Biotech

Earnings

Penny Stocks

Technicals

Small Cap

Analyst Ratings

General

Karyopharm Therapeutics (NASDAQ: KPTI) has been beaten down lately with too much selling pressure.

Down -12.14% in 4 Weeks, Here&#39;s Why Karyopharm Therapeutics Looks Ripe for a Turnaround

Health Care

Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced the presentation of updated exploratory subgroup analyses from the SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the virtual American Society of Clinical 

Karyopharm&#39;s Selinexor Shows Progression-Free Survival of 27.4 Months In Endometrial Cancer With Certain Mutation

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics Inc

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

– Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company On Track to Complete Enrollment in 1H 2025 –&nbsp;
– Recently Announced Key Leadership Changes, including the Appointment of Lori Macomber as Chief Financial Officer and Brendan Strong as SVP of Investor Relations and Corporate Communications –&nbsp;
– Preliminary Unaudited Full Year 2024 Total Revenue and U.S. XPOVIO&#xAE;&nbsp;(selinexor) Net Product Revenue Expected to be Approximately $145 Million and $113 Million, Respectively –
NEWTON, Mass., Jan. 13, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2024 achievements and 2025 objectives.

Guidance

Management

Karyopharm Therapeutics Announces Phase 3 SENTRY Trial Data For Selinexor In JAKi-Naïve Myelofibrosis Expected In H2 2025; Enrollment By H1 2025; Lori Macomber Appointed Chief Financial Officer; Preliminary 2024 Revenue At $145M And XPOVIO Sales Reached $113M

Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company.
Ms. Macomber has over 20 years of diversified experience in leading growth and driving financial strategies for life science companies. She has a proven track record in financial management for companies ranging from start-up to Fortune 500 and has also successfully supported various collaboration partnerships, business development activities and licensing deals. Most recently, she served as Chief Financial Officer at Legend Biotech Corporation, a publicly traded, commercial-stage biopharmaceutical company.&nbsp; Previously, Ms. Macomber held leadership roles of increasing responsibility with Ametek PDS, Cello Health, Eli Lilly and Company, and Pfizer (formerly Pharmacia). Ms. Macomber holds a Bachelor of Science in Accounting from Pennsylvania State University and is a Certified Public Accountant.

Karyopharm Tapped Lori Macomber Of Legend Biotech As CFO, Effective January 3

Shares of Edgewise Therapeutics, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) rose sharply in today's pre-market trading after the company reported topline results from Phase 2 CANYON trial of Sevasemten in individuals with <a href="https://www.benzinga.com/quote/EWTX/news">becker muscular dystrophy</a>.
Edgewise Therapeutics shares jumped 26.5% to $35.00 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) gained 59.4% to $2.28 in pre-market trading after adding 9% on Friday.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) gained 48.6% to $2.60 in pre-market trading after falling over 5% on Friday.</li>
<li>U-BX Technology Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBXG#NASDAQ">UBXG</a>) gained 32.3% to $4.40 in pre-market trading.</li>
<li>PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) rose 22.8% to $25.00 in pre-market trading after the company reported positive results from ELEVATE IPF, a Phase 2b randomized, double-blind, active- and placebo-controlled, dose-ranging trial evaluating deupirfenidone (LYT-100) at two dose levels three times a day (TID) over 26 weeks in patients with idiopathic pulmonary fibrosis (IPF).</li>
<li>BTC Digital Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) gained 22.8% to $7.84 in pre-market trading.</li>
<li>Sagimet Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) climbed 17.2% to $5.15 in pre-market trading after falling over 3% on Friday.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) gained 14.4% to $30.72 in pre-market trading.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) gained 13.8% to $0.2736 in pre-market trading after gaining 5% on Friday.</li>
<li>BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) gained 9.1% to $5.64 in pre-market trading following a 9% decline on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Akoustis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) shares tumbled 39.8% to $0.0410 in pre-market trading after the company filed for Chapter 11 and initiated strategic sale of business amid Qorvo legal dispute.</li>
<li>Roadzen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDZN#NASDAQ">RDZN</a>) declined 32.6% to $1.20 in pre-market trading after the company priced its $2.5 million public offering of 2 million common shares at $1.25 per share.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares fell 23.9% to $0.2160 in pre-market trading after the company announced the receipt of Nasdaq Listing Delinquency Notice.</li>
<li>Karyopharm Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) fell 21.6% to $0.55 in pre-market trading.</li>
<li>AtlasClear Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NASDAQ">ATCH</a>) dipped 20.5% to $0.1750 in pre-market trading.</li>
<li>Innate Pharma S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares dipped 19.2% to $2.44 in pre-market trading after jumping 96% on Friday. The company, last week. announced its TELLOMAK Phase 2 trial of Lacutamab demonstrated significant symptom relief and quality of life improvements.</li>
<li>22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares fell 17.5% to $0.0404 in pre-market trading after dipping 33% on Friday.</li>
<li>Santech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEC#NASDAQ">STEC</a>) fell 17.2% to $0.63 in pre-market trading.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 12.5% to $31.85 in pre-market trading following reports suggesting the company tapped Evercore to raise capital and is considering raising equity and debt.</li>
<li>SPI Energy Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPI#NASDAQ">SPI</a>) fell 12.1% to $0.34 in today's pre-market trading after jumping over 10% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42482639/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding the evolving treatment landscape in endometrial cancer and any implications this may have with respect to the Company's Phase 3 XPORT-EC-042 trial. In light of this, Karyopharm does not plan to discuss its endometrial cancer program during the Piper Sandler 36th&nbsp;Annual Healthcare Conference being held in New York, NY today. The Company intends to provide an update on its endometrial cancer program as soon as practical following the discussion with FDA.

Government

Regulations

Karyopharm Therapeutics Will Update On Endometrial Cancer Program Following US FDA Meet

Piper Sandler analyst Christopher Raymond maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Overweight and raises the price target from $4 to $5.

Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $5

2024&nbsp;Financial Outlook
Based on its current operating plans, Karyopharm has further narrowed its guidance for full year 2024 as follows:
<ul>
<li>Total revenue to be in the range of $145.0 million to $155.0 million as compared to the Company's prior guidance of $145.0 million to $160.0 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.</li>
<li>U.S. XPOVIO net product revenue to be in the range of $110.0 million to $115.0 million as compared to the Company's prior guidance of $105.0 million to $120.0 million.</li>
<li>R&amp;D and selling, general and administrative (SG&amp;A) expenses to be in the range of $255.0 million to $265.0 million, which includes approximately $20.0 million estimated non-cash stock-based compensation expense, as compared to the Company's prior guidance of $250.0 million to $265.0 million.</li>
<li>The Company expects that its existing cash, cash equivalents and investments, the revenue it expects to generate from XPOVIO net product sales and its license agreements and ongoing disciplined expense management and cost saving measures, will be sufficient to fund its planned operations into the first quarter of 2026.</li>
</ul>

Karyopharm Expects 2024 Sales Of $145M-$155M Versus Prior Guidance Of $145M-$160M And Consensus Of $152.352M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 13.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $38.78 million which beat the analyst consensus estimate of $37.79 million by 2.63 percent. This is a 7.70 percent increase over sales of $36.01 million the same period last year.

Karyopharm Therapeutics Q3 2024 GAAP EPS $(0.26), Inline, Sales $38.78M Beat $37.79M Estimate

WIIM

Karyopharm Therapeutics shares are trading higher after the company announced that, following the FDA feedback, it will be replacing TSS50, one of the co-primary endpoints in the Phase 3 SENTRY Trial with Abs-TSS.

<ul>
<li>Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA.</li>
<li>Abs-TSS measures the average improvement in patient symptom scores over 24 weeks relative to the patient's baseline symptom score.&nbsp;</li>
<li>Spleen Volume Response Rate ≥ 35% (SVR35) Remains a Co-primary Endpoint.</li>
<li>Promising Improvement in&nbsp;Abs-TSS and SVR35 from Phase 1 Trial of Selinexor in Combination with Ruxolitinib Adds Confidence in Phase 3 SENTRY Trial.</li>
<li>Proactively Increasing Total Sample Size of the SENTRY Trial to Approximately 350 Patients to Further Increase the Statistical Powering; Expected Top-line Data Read-out Remains in 2H 2025.</li>
</ul>
&nbsp;

Karyopharm Therapeutics Announced That, Following FDA Feedback, The Company Will Be Replacing TSS50, One Of The Co-primary Endpoints In The Phase 3 SENTRY Trial With Abs-TSS

<h3>Gainers</h3>
<ul>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock increased by 13.4% to $3.9 during Monday's after-market session. The company's market cap stands at $165.5 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares moved upwards by 10.45% to $0.52. The company's market cap stands at $20.7 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) shares rose 9.76% to $17.2. The company's market cap stands at $42.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares increased by 5.81% to $0.74. The company's market cap stands at $50.6 million. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 5.75% to $0.48. The market value of their outstanding shares is at $41.2 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares increased by 5.41% to $0.93. The company's market cap stands at $132.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) shares decreased by 15.4% to $14.0 during Monday's after-market session. The market value of their outstanding shares is at $830.4 million. </li>
<li>Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) stock decreased by 9.4% to $0.75. The market value of their outstanding shares is at $93.7 million. </li>
<li>Pennant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNTG#NASDAQ">PNTG</a>) stock decreased by 7.57% to $33.0. The company's market cap stands at $996.8 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock decreased by 6.26% to $0.13. The market value of their outstanding shares is at $14.6 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock decreased by 5.0% to $0.65. The company's market cap stands at $6.5 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock decreased by 5.0% to $0.72. The market value of their outstanding shares is at $34.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

BNGO

CGTX

IGMS

NIVF

OMIC

PNTG

RPTX

12 Health Care Stocks Moving In Monday's After-Market Session

Karyopharm Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kpti#NASDAQ">KPTI</a>) has been beaten down lately with too much selling pressure. While the stock has lost 12.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.
<h2>Here is How to Spot Oversold Stocks</h2>
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock&#39;s price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
<h2>Here&#39;s Why KPTI Could Experience a Turnaround</h2>
The RSI reading of 28.75 for KPTI is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.
The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for KPTI has increased 19.5%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, KPTI currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock&#39;s potential turnaround in the near term.
<a href="https://www.zacks.com/stock/news/2332006/down-12-14-in-4-weeks-here-s-why-karyopharm-therapeutics-kpti-looks-ripe-for-a-turnaround?cid=CS-BENZ-FT-tale_of_the_tape|rsi-2332006">To read this article on Zacks.com click here.</a>

Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround

RBC Capital analyst Brian Abrahams reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and maintains $3 price target.

RBC Capital Reiterates Outperform on Karyopharm Therapeutics, Maintains $3 Price Target

Baird analyst Mitch Collett maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and lowers the price target from $8 to $5.

Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $5

Karyopharm Revises FY24 Total Revenue Outlook From $140M - $160M To $145M - $160M, Est $145.44M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 31.03 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $42.786 million which beat the analyst consensus estimate of $36.179 million by 18.26 percent. This is a 13.86 percent increase over sales of $37.579 million the same period last year.

Earnings Beats

Karyopharm Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.30) Estimate, Sales $42.786M Beat $36.179M Estimate

HC Wainwright &amp; Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and lowers the price target from $8 to $7.

Comments

Karyopharm Therapeutics

Karyopharm Therapeutics (KPTI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga